Literature DB >> 8284687

A progress report on the outpatient treatment of patients with advanced renal cell carcinoma using subcutaneous recombinant interleukin-2.

J Buter1, D T Sleijfer, W T van der Graaf, E G de Vries, P H Willemse, N H Mulder.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8284687

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  7 in total

Review 1.  Monoclonal antibodies in solid tumours: approaches to therapy with emphasis on gynaecological cancer.

Authors:  G Fleckenstein; R Osmers; J Puchta
Journal:  Med Oncol       Date:  1998-12       Impact factor: 3.064

2.  Current status of cytokine therapy in management of patients with metastatic renal cell carcinoma.

Authors:  Anil K Kapoor; Sébastien J Hotte
Journal:  Can Urol Assoc J       Date:  2007-06       Impact factor: 1.862

3.  Prognostic factors for survival in patients with advanced renal cell carcinoma treated with interleukin-2 and interferon-alpha.

Authors:  L Canobbio; A Rubagotti; L Miglietta; D Cannata; A Curotto; D Amoroso; F Boccardo
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

4.  Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.

Authors:  S R Johnston; D O Constenla; J Moore; H Atkinson; R P A'Hern; G Dadian; P G Riches; M E Gore
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

5.  Biological and Molecular Factors Predicting Response to Adoptive Cell Therapies in Cancer.

Authors:  Gerardo Ferrer; Damiana Álvarez-Errico; Manel Esteller
Journal:  J Natl Cancer Inst       Date:  2022-07-11       Impact factor: 11.816

6.  Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma.

Authors:  P F Geertsen; M E Gore; S Negrier; J M Tourani; H von der Maase
Journal:  Br J Cancer       Date:  2004-03-22       Impact factor: 7.640

7.  Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II trial.

Authors:  A Ravaud; N Trufflandier; J M Ferrière; M Debled; J Palussière; L Cany; R Gaston; S Mathoulin-Pélissier; B N Bui
Journal:  Br J Cancer       Date:  2003-12-15       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.